{"id":110585,"date":"2026-07-31T20:05:10","date_gmt":"2026-07-31T20:05:10","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/110585\/"},"modified":"2026-07-31T20:05:10","modified_gmt":"2026-07-31T20:05:10","slug":"10x-genomics-lausanne-university-hospital-collaborate-on-single-cell-cancer-diagnostics","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/110585\/","title":{"rendered":"10x Genomics, Lausanne University Hospital Collaborate on Single-Cell Cancer Diagnostics"},"content":{"rendered":"<p><a href=\"https:\/\/clpmag.com\/lab-essentials\/lab-automation\/spt-labtech-10x-genomics-partner-single-cell-workflow-automation\/\" class=\"text-editor-link-class\" rel=\"nofollow noopener\" target=\"_blank\">10x Genomics<\/a> and Lausanne University Hospital have entered a multi-year research collaboration to advance diagnostic applications of single-cell and spatial technologies in oncology.<\/p>\n<p>The study intends to use the <a href=\"https:\/\/clpmag.com\/diagnostic-technologies\/flow-cytometry\/library-preparation-systems\/10x-genomics-launches-next-generation-of-chromium-flex-to-scale-single-cell-research\/\" class=\"text-editor-link-class\" rel=\"nofollow noopener\" target=\"_blank\">10x Genomics Flex<\/a> Apex and <a href=\"https:\/\/clpmag.com\/uncategorized\/10x-genomics-launches-xenium-protein-integrated-rna-protein-analysis\/\" class=\"text-editor-link-class\" rel=\"nofollow noopener\" target=\"_blank\">Xenium platforms<\/a>, with plans to expand to the Atera platform, to examine tumor samples from patients with advanced cancer. These patients are currently undergoing a detailed evaluation by a clinical molecular tumor board. The research aims to identify clinically relevant biomarkers that may help predict treatment response and cancer prognosis, while supporting the development of new diagnostics.<\/p>\n<p>The study is expected to include hundreds of patients across multiple solid tumor types, including <a href=\"https:\/\/clpmag.com\/diagnostic-technologies\/molecular-diagnostics\/rna-testing-improves-met-exon-14-detection-lung-cancer\/\" class=\"text-editor-link-class\" rel=\"nofollow noopener\" target=\"_blank\">non-small cell lung cancer<\/a>, <a href=\"https:\/\/clpmag.com\/disease-states\/cancer\/breast\/ibex-breast-cancer-diagnostic-tools-ivdr-certification\/\" class=\"text-editor-link-class\" rel=\"nofollow noopener\" target=\"_blank\">breast cancer<\/a>, bladder cancer, and melanoma. Researchers plan to integrate single-cell and spatial biology data with clinical outcomes to better understand mechanisms of response and resistance across various therapeutic approaches, such as antibody-drug conjugates, bispecific antibodies, and <a href=\"https:\/\/clpmag.com\/diagnostic-technologies\/digital-pathology\/ai-pathology-tool-predicts-immunotherapy-response-rare-cancers\/\" class=\"text-editor-link-class\" rel=\"nofollow noopener\" target=\"_blank\">immune checkpoint inhibitors<\/a>.<\/p>\n<p>\u201cThis collaboration brings together complementary expertise in spatial biology, pathology, computational artificial intelligence and clinical precision oncology to address one of the biggest challenges in cancer care: predicting which patients will benefit from treatment,\u201d says <a href=\"https:\/\/www.chuv.ch\/en\/bdsc\/research-group\/web_run_24\/gottardo-group\" class=\"text-editor-link-class\" rel=\"nofollow noopener\" target=\"_blank\">Raphael Gottardo<\/a>, professor and director of the Biomedical Data Science Center, Lausanne University Hospital, in a release. \u201cTogether, we aim to discover clinically actionable biomarkers that improve patient selection and bring more precise treatment decisions closer to routine clinical care.\u201d<\/p>\n<p>The collaboration also intends to investigate how these single-cell and spatial technologies can be deployed clinically alongside current standard-of-care assays. The project is expected to generate a multimodal resource that integrates data to enable the discovery of biomarkers for treatment response and resistance. <\/p>\n<p>Furthermore, the teams plan to evaluate how these biomarkers could be incorporated into future clinical reporting frameworks to support personalized treatment planning and decision-making by molecular tumor boards.<\/p>\n<p>\u201cThe promise of precision oncology depends on understanding the biology that helps determine which therapies are most likely to benefit a given patient,\u201d says Serge Saxonov, co-founder and CEO of 10x Genomics, in a release. \u201cWe believe single cell and spatial technologies provide a fundamentally richer view of the biology within tumors and their microenvironment, creating opportunities to discover biomarkers that can help guide treatment decisions and enable future diagnostic approaches in cancer care.\u201d<\/p>\n<p>ID <a href=\"https:\/\/www.dreamstime.com\/professional-digital-microscope-science-background-professional-digital-microscope-scientist-background-image107086721\" class=\"text-editor-link-class\" rel=\"nofollow noopener\" target=\"_blank\">107086721<\/a> \u00a9 <a href=\"https:\/\/www.dreamstime.com\/toxawww_info\" class=\"text-editor-link-class\" rel=\"nofollow noopener\" target=\"_blank\">Toxawww<\/a> | <a href=\"http:\/\/Dreamstime.com\" class=\"text-editor-link-class\" rel=\"nofollow noopener\" target=\"_blank\">Dreamstime.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"10x Genomics and Lausanne University Hospital have entered a multi-year research collaboration to advance diagnostic applications of single-cell&hellip;\n","protected":false},"author":2,"featured_media":110586,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[9],"tags":[5798,405,225,14441,6114,42433,20440,24753,6724,94,53995,53996,26029,6304,53997,42439,5795,53998],"class_list":["post-110585","post","type-post","status-publish","format-standard","has-post-thumbnail","category-lausanne","tag-10x-genomics","tag-antibody-drug-conjugates","tag-artificial-intelligence","tag-biomarkers","tag-bispecific-antibodies","tag-cancer-diagnostics","tag-clinical-diagnostics","tag-immune-checkpoint-inhibitors","tag-immunotherapy","tag-lausanne","tag-lausanne-university-hospital","tag-molecular-tumor-board","tag-oncology-research","tag-precision-medicine","tag-single-cell-analysis","tag-solid-tumors","tag-spatial-biology","tag-tumor-biomarkers"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117016390734343608","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/110585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=110585"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/110585\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/110586"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=110585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=110585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=110585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}